Key Highlights

  • EBR Systems shares were trading at $0.158 during the 13 November 2026 session, down 7.35%.
  • The company completed 40 commercial WiSE System implants in Q3 2026, taking the total to 157.
  • A A$150 million Capital raising was completed to fund commercial operations and Manufacturing scale-up.

During the Trading session on 13 November 2026, EBR Systems Inc (ASX:EBR) shares were trading at $0.158, down 7.35%, while the S&P/ASX 200 was down 0.73% at 9,079.70 at 12:39 pm AEDT. EBR develops the WiSE wireless cardiac pacing system, which is being commercialised in the United States. Its latest update was its quarterly activity report and Form 10-Q submission, dated 10 November 2026.

Implants and commercial progress

EBR completed 40 commercial WiSE System implants in the third quarter of 2026, taking total commercial implants across the pilot launch phase and limited market release to 157. The company said early results are emerging in the fourth quarter following a realignment of its US commercial organisation. It is actively searching for a chief commercial officer and is focusing on account utilisation, procedural frequency and field training.

Reimbursement and regulatory milestones

Medicare inpatient reimbursement for eligible WiSE procedures increased from 1 October 2026. A proposed National Coverage Determination decision is expected in early December 2026. The Santa Clara Facility achieved ISO 13485 certification, and an FDA pre-approval inspection was completed. The WiSE Coupler was commercially launched in the United States.

Funding and cash

An A$150 million capital raising was completed to fund commercial operations and manufacturing scale-up, with a stated focus on financial discipline. EBR held cash, cash equivalents, restricted cash and marketable securities of US$95.8 million, or A$137.4 million, at 30 September 2026.

Sector context

Wireless cardiac pacing devices must clear regulatory approvals and secure reimbursement before hospitals adopt them at scale. Coverage decisions and procedure payments heavily influence how quickly new cardiac devices are used, and early commercial launches often show uneven order and implant patterns.

Risks investors are watching

Implant numbers remain modest, and the company's commercial organisation has been realigned, with a chief commercial officer still being sought. The Medicare coverage decision is pending and its outcome is not certain. Cash of about A$137 million will fund operations, but the company has said it is scaling up manufacturing.

What to watch ahead

Investors will look for the proposed National Coverage Determination decision in early December 2026, implant volumes in the fourth quarter, and the appointment of a chief commercial officer.

Final Word

EBR's latest quarterly update reports rising implant numbers, a higher reimbursement rate and a completed capital raising. The coverage decision in December will be a key next test.